相似文献
1
The influence of ketamine on drug discovery in depression.
Drug Discov Today. 2019 Oct;24(10):2033-2043. doi: 10.1016/j.drudis.2019.07.007. Epub 2019 Aug 2.
2
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
Curr Top Behav Neurosci. 2022;56:141-167. doi: 10.1007/7854_2022_313.
3
Ketamine: Mechanisms and Relevance to Treatment of Depression.
Annu Rev Med. 2024 Jan 29;75:129-143. doi: 10.1146/annurev-med-051322-120608. Epub 2023 Sep 20.
4
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Int J Mol Sci. 2022 Sep 28;23(19):11450. doi: 10.3390/ijms231911450.
5
The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Adv Exp Med Biol. 2023;1411:487-512. doi: 10.1007/978-981-19-7376-5_21.
6
Ketamine for Major Depressive Disorder.
Curr Top Behav Neurosci. 2024;66:131-147. doi: 10.1007/7854_2023_453.
7
The rapid-onset antidepressant effect of ketamine: More surprises?
J Clin Pharm Ther. 2018 Apr;43(2):308-311. doi: 10.1111/jcpt.12656. Epub 2017 Nov 26.
8
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Epidemiol Psychiatr Sci. 2019 Dec 16;29:e79. doi: 10.1017/S2045796019000751.
9
Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
Behav Brain Res. 2011 Oct 10;224(1):107-11. doi: 10.1016/j.bbr.2011.05.035. Epub 2011 Jun 6.
10
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).
Adv Exp Med Biol. 2024;1456:49-66. doi: 10.1007/978-981-97-4402-2_3.
引用本文的文献
1
Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
CNS Drugs. 2024 Nov;38(11):869-890. doi: 10.1007/s40263-024-01114-y. Epub 2024 Aug 16.
2
Modulation of habenular and nucleus accumbens functional connectivity by ketamine in major depression.
Brain Behav. 2024 Jun;14(6):e3511. doi: 10.1002/brb3.3511.
3
Alterations in Astrocytic Regulation of Excitation and Inhibition by Stress Exposure and in Severe Psychopathology.
J Neurosci. 2022 Sep 7;42(36):6823-6834. doi: 10.1523/JNEUROSCI.2410-21.2022.
4
Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors.
J Neurochem. 2024 Jun;168(6):1097-1112. doi: 10.1111/jnc.16070. Epub 2024 Feb 7.
5
Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression.
Anal Bioanal Chem. 2024 Apr;416(9):2301-2318. doi: 10.1007/s00216-024-05136-9. Epub 2024 Jan 30.
6
Microdosing ketamine in does not inhibit SERT like SSRIs, but causes behavioral changes mediated by glutamate and serotonin receptors.
bioRxiv. 2023 Nov 8:2023.11.07.566121. doi: 10.1101/2023.11.07.566121.
7
Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects.
Ibrain. 2023 Feb 20;9(1):90-101. doi: 10.1002/ibra.12094. eCollection 2023 Spring.
8
Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin.
Neuronal Signal. 2023 Jul 13;7(2):NS20220054. doi: 10.1042/NS20220054. eCollection 2023 Jul.
9
Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Apr;8(4):361-386. doi: 10.1016/j.bpsc.2022.11.005. Epub 2022 Nov 26.
10
Unraveling the Mysteries of Mental Illness With Psilocybin.
Cureus. 2022 May 27;14(5):e25414. doi: 10.7759/cureus.25414. eCollection 2022 May.
本文引用的文献
1
Do antidepressants restore lost synapses?
Science. 2019 Apr 12;364(6436):129-130. doi: 10.1126/science.aax0719.
2
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.
Science. 2019 Apr 12;364(6436). doi: 10.1126/science.aat8078.
3
()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions.
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.
4
State of the art opioid-sparing strategies for post-operative pain in adult surgical patients.
Expert Opin Pharmacother. 2019 Jun;20(8):949-961. doi: 10.1080/14656566.2019.1583743. Epub 2019 Feb 27.
5
Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function.
Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.
6
Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
CNS Drugs. 2019 Mar;33(3):265-282. doi: 10.1007/s40263-019-00605-7.
7
A report of affective switching associated with ketamine: The case of ketamine-induced mania is not closed.
Bipolar Disord. 2019 Mar;21(2):176-178. doi: 10.1111/bdi.12728. Epub 2019 Feb 1.
8
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Drug Discov Today. 2019 Feb;24(2):606-615. doi: 10.1016/j.drudis.2018.11.007. Epub 2018 Nov 14.
9
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135. doi: 10.1093/ijnp/pyy094.
10
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
Mol Psychiatry. 2020 Jul;25(7):1580-1591. doi: 10.1038/s41380-018-0284-1. Epub 2018 Oct 29.
Zotero 插件